Lead Product(s): AGMB-101
Therapeutic Area: Immunology Product Name: AGMB-101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $74.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 10, 2021
Proceeds to further advance lead compound AGMB-101 and expand pipeline in inflammatory, metabolic and fibrotic diseases.